Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and HypertensionNovelty and Significance [Clinical Trials]

In conclusion, sacubitril/valsartan treatment for 8 weeks did not elicit clinically relevant changes in exercise-induced lipolysis or substrate oxidation in obese patients with hypertension, implying that its beneficial cardiovascular effects cannot be explained by changes in lipid metabolism during exercise.Clinical Trial Registration—URL: https://www.clinicaltrials.gov. Unique identifier: NCT01631864.

Source: Hypertension - December 13, 2017 Category: Cardiology Authors: Stefan Engeli, Rudi Stinkens, Tim Heise, Marcus May, Gijs H. Goossens, Ellen E. Blaak, Bas Havekes, Thomas Jax, Diego Albrecht, Parasar Pal, Uwe Tegtbur, Sven Haufe, Thomas H. Langenickel, Jens Jordan Tags: Metabolism Original Articles Source Type: research